A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

by palligoelme@gmail.com | Mar 6, 2026 | Clinical Trials

​ Conditions: Narcolepsy Type 1 Interventions: Drug: ALKS 2680 Dose 1; Drug: ALKS 2680 Dose 2; Drug: Placebo Sponsors: Alkermes, Inc. Not yet recruiting Conditions: Narcolepsy Type 1 Interventions: Drug: ALKS 2680 Dose 1; Drug: ALKS 2680 Dose 2; Drug: Placebo...

Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.

by palligoelme@gmail.com | Mar 6, 2026 | Clinical Trials

​ Conditions: Anxiety; Depression – Major Depressive Disorder; Bipolar; Schizophenia Disorder Sponsors: Shalvata Mental Health Center; University Hospital, Antwerp; San Raffaele University Hospital, Italy; Oslo University Hospital Active, not...

Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions.

by palligoelme@gmail.com | Mar 5, 2026 | Clinical Trials

​ Conditions: Colorectal Polyps Interventions: Device: SUBMO® Submucosal Injection; Device: Normal Saline (0.9% Sodium Chloride) with Surface Dye Injection Sponsors: i+Med S.Coop.; Hospital Universitario Basurto; Hospital de Cruces; Hospital Sant Joan de Deu; Fundació...

Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.

by palligoelme@gmail.com | Mar 5, 2026 | Clinical Trials

​ Conditions: Ventral Hernias; Cytoreductive Surgery Sponsors: Jules Bordet Institute Recruiting Conditions: Ventral Hernias; Cytoreductive Surgery Sponsors: Jules Bordet Institute Recruiting 

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

by palligoelme@gmail.com | Mar 5, 2026 | Clinical Trials

​ Conditions: Chronic Kidney Disease Sponsors: AstraZeneca Recruiting Conditions: Chronic Kidney Disease Sponsors: AstraZeneca Recruiting